Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions

Fig. 3

Kaplan–Meier survival curves for breast cancer patients (n = 96) with high and low enhancer of zeste homolog 2 (EZH2) expression. Kaplan–Meier survival curves for breast cancer patients with high and low enhancer of zeste homolog 2 (EZH2) expression in (a) disease-free survival in patients with primary lesions, b overall survival in patients after primary surgery with primary lesions, c overall survival in patients after recurrence with primary lesions, d disease-free survival in patients with metastatic lesions, e overall survival in patients after primary surgery with metastatic lesions, and (f) overall survival in patients after recurrence with metastatic lesions

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us